1. Scrip
  2. >>Business

Servier’s Kamoun On Breaking Brain Cancer Barriers By Harnessing Cancer Metabolism

 
• By Ayisha Sharma

The private French firm’s new global head of R&D oncology spoke with Scrip about its two-pronged oncology strategy and its high hopes for the advanced glioma candidate, vorasidenib, which may improve upon Tibsovo.  

Multicolor image of tumor cells under microscope
Several Firms Have Struggled To Develop Successful Glioma Drugs • Source: Shutterstock

Les Laboratoires Servier is determined to tackle the challenging glioma space with a cancer metabolism-based asset gained through its acquisition of Agios Pharmaceuticals, Inc.’ oncology portfolio, new executive Walid Kamoun told Scrip.

Kamoun was appointed global head of the French firm’s R&D Oncology in April, bringing 20 years of industry experience

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Mission Vision: How Roche Hopes To Impact Eye Health Outcomes In APAC

 
• By Anju Ghangurde

Roche Pharmaceuticals’ area head, Asia Pacific, outlines how the Swiss group is helping nurture the wider ecosystem and setting itself up for a bigger play in the ophthalmology space by combining scientific expertise with regional insights.

Apnimed’s AD109 Could Be A Wake-Up Call For Sleep Apnea Market

 
• By Joseph Haas

The first of two Phase III trials in obstructive sleep apnea showed Apnimed’s combination pill can offer a therapeutic alternative to entrenched CPAP devices.

First Blood-Based Test Cleared For Alzheimer’s Boosts Anti-Amyloid Drugs

 
• By Mandy Jackson

The US FDA approval of Fujirebio’s Lumipulse should boost access to medicines like Eisai’s Leqembi and Lilly’s Kisunla; the firms are praising patients’ access to earlier diagnoses.